Abstracts tagged "rheumatoid arthritis"

Abstract Number: PP02 • ACR Convergence 2022
Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic
Marie-Claude Beaulieu¹, Ines Colmegna², Nathalie Amiable³, Jean Légaré⁴ and Paul Fortin⁵, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³CHU de Québec, Quebec, QC, Canada, ⁴QC, Canada, ⁵CHU de Quebec - Universite Laval, Quebec, QC, Canada
Background/Purpose: The COVID pandemic was particularly difficult for persons like me living with rheumatoid arthritis and immunosuppressed. I had to impose myself months of isolation…
Abstract Number: 0005 • ACR Convergence 2022
The Rheumatology Access Expansion (RAE) Initiative: Improving Rheumatoid Arthritis Care on Navajo Nation Through Primary Care Provider Education
Jennifer Mandal¹, Tabitha Carroway², Zara Izadi¹, Gwendolyn Grant³, Mary Margaretten², Starla Blanks⁴, Nataya Cabrera⁴, Peter Emanuel², Jeannie Hong⁵, Sheryl McCalla⁴, John McDougall⁶, Catherine Nasrallah⁷, McKinsey Pillsbury² and Jinoos Yazdany², ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Centura Health, Durango, CO, ⁴American College of Rheumatology, Atlanta, GA, ⁵Phoenix Indian Medical Center/Indian Health Service, Phoenix, AZ, ⁶Northern Navajo Medical Center - Shiprock, NM, Shiprock, NM, ⁷UCSF, San Francisco
Background/Purpose: The burden of rheumatoid arthritis (RA) in the United States falls disproportionately on communities of color and rural populations. The Navajo Nation is the…
Abstract Number: 0072 • ACR Convergence 2022
Geographical Patterns of Healthcare Utilization Among RA and OA Patients
Sofia Pedro¹, Luke Desilet², Patricia Katz³ and Kaleb Michaud², ¹Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ²University of Nebraska Medical Center, Omaha, NE, ³UCSF, San Rafael, CA
Background/Purpose: Rural residence has been associated with disparities in healthcare-related outcomes in both rheumatic diseases and other chronic conditions. A primary causal pathway for this…
Abstract Number: 0184 • ACR Convergence 2022
Exploring Patient Journeys and Education Needs of Hispanic Individuals with Rheumatoid Arthritis
Daniel Hernandez¹, Julio Bravo², Juan Maya Villamizar³, William Benjamin Nowell¹, Oscar Soto-Raices⁴, Angel Tapia⁵, Guillermo Valenzuela⁶ and Shilpa Venkatachalam⁷, ¹Global Healthy Living Foundation, Nyack, NY, ²Novant, Winston-Salem, NC, ³Rheumatology Center of Palm Beach, PLLC, Boca Raton, FL, ⁴Fundación FER, San Juan, PR, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁷Global Healthy Living Foundation, New York, NY
Background/Purpose: There is little research on rheumatoid arthritis (RA) in the US Hispanic population (< 0.2% of publications on RA indexed in PubMed.gov), but it…
Abstract Number: 0247 • ACR Convergence 2022
Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association
Maria Vassilaki¹, Stephanie Duong¹, Chanakya Kodishala¹, Rabia Javed¹, Michelle Mielke², John Davis¹, Cynthia Crowson³ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Wake Forest University School of Medicine, Winston-Salem, NC, ³Mayo Clinic, Eyota, MN
Background/Purpose: Instrumental activities of daily living (iADLs) are complex abilities necessary for independent living involving higher cognitive functions and decline earlier than basic (b) ADLs…
Abstract Number: 0263 • ACR Convergence 2022
DAS28 (disease Activity Score) Elevations in Patients with Rheumatoid Arthritis (RA) Who Have Comorbid Fibromyalgia Are Explained by Elevated Tender Joint Counts as Much as by Elevated Patient Global Assessment
Sandhya shri Kannayiram¹, Juan Schmukler², Nicola Goodson³ and Theodore Pincus², ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³University Hospital Aintree, Liverpool, United Kingdom
Background/Purpose: Several reports indicate that patient global assessment (PATGL) may elevate DAS28 (disease activity score 28) and/or other indices in patients with rheumatoid arthritis (RA),…
Abstract Number: 0280 • ACR Convergence 2022
Safety of Filgotinib in Patients with RA: Laboratory Analysis Results from a Long-Term Extension Study
Maya Buch¹, James Galloway², Ennio Giulio Favalli³, Arnaud Constantin⁴, Patrick Durez⁵, Paul Van Hoek⁶, Christopher Watson⁷, Pieter-Jan Stiers⁶, Vijay Rajendran⁸, Katrien Van Beneden⁶, Tsutomu Takeuchi⁹ and BERNARD COMBE¹⁰, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²King's College London, London, United Kingdom, ³University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁴Toulouse University Hospital and University Toulouse III Paul Sabatier, Toulouse, France, ⁵Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁸Galapagos NV, Gent, Belgium, ⁹Keio University and Saitama Medical University, Tokyo, Japan, ¹⁰Montpellier University, Montpellier, France
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor, approved for treatment of moderate to severe active RA in Europe, the UK, and…
Abstract Number: 0297 • ACR Convergence 2022
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Adriana Kakehasi², Neil Basu³, David A. Walsh⁴, Andra Balanescu⁵, Clifton Bingham⁶, Andrew Garrison⁷, Ivan Lagunes⁸, sander strengholt⁹, Ralph Lippe¹⁰ and Maxime Dougados¹¹, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴University of Nottingham, Nottingham, United Kingdom, ⁵University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁶Johns Hopkins University, Baltimore, MD, ⁷AbbVie, Inc., North Chicago, IL, ⁸AbbVie, Inc., Mettawa, IL, ⁹AbbVie, Inc., Abcoude, Netherlands, ¹⁰AbbVie, Inc, Wiesbaden, Germany, ¹¹Université de Paris, Paris, France
Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…
Abstract Number: 0315 • ACR Convergence 2022
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Evgeny Nasonov¹, Eugen Feist², Michael Luggen³, Sergey Yakushin⁴, Daria Bukhanova⁵, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁵ and Josef Smolen⁷, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ³University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Ryazan State Medical University named after academician I.P. Pavlov, Ryazan, Russia, ⁵R-Pharm JSC, Moscow, Russia, ⁶R-Pharm, Moscow, Russia, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…
Abstract Number: 0554 • ACR Convergence 2022
Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset
Megan Hanlon¹, Mary Canavan², conor Smith³, Achilleas Floudas⁴, Nuno Neto⁵, Qingxuan Song⁶, Phil Gallagher⁷, Ronan Mullan⁸, Conor Hurson⁹, Barry Moran⁵, Michael Monaghan⁵, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon⁵, ¹Molecular Rheumatology, Dublin, Ireland, ²Trinity College, Dublin, Ireland, ³bTrinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁵Trinity College Dublin, Dublin, Ireland, ⁶Janssen Research and Development, LLC, Spring House, PA, ⁷St Vincent's University Hospital, Dublin, Ireland, ⁸Tallaght University Hospital, Dublin, Ireland, ⁹St Vincents University Hospital, Dublin, Ireland, ¹⁰Janssen Research, Collegeville, PA, ¹¹St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Synovial-tissue macrophages significantly contribute to Rheumatoid Arthritis, yet the precise nature/function of macrophage subsets within the inflamed joint remains unexplored. Here we explore the…
Abstract Number: 0595 • ACR Convergence 2022
Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis
Janani Sundaresan¹, Ittai B. Muller¹, Marry Lin¹, Floris P.J.G. Lafeber², Paco Welsing², Maurits C.F.J. De Rotte³, Maja Bulatovic-Calasan⁴, Conny van der Laken⁵, Robert De Jonge⁶ and Gerrit Jansen⁵, ¹Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Clinical Chemistry, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUmc, Amsterdam, The Netherlands; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁶Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Tocilizumab (TCZ), a biologic Disease Modifying Anti-Rheumatic Drug, elicits an immune-modulating effect by binding to the interleukin 6 receptor and inhibiting downstream signaling. Despite…
Abstract Number: 0612 • ACR Convergence 2022
Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response
Siddharth Jain¹, Bidya Laishangtham¹, Aastha Khullar¹, Biman Saikia¹ and Varun Dhir², ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: It is still unclear whether Natural Killer (NK) and Natural Killer T (NKT) cells play a pathogenic or protective role in Rheumatoid Arthritis (RA).…
Abstract Number: 0704 • ACR Convergence 2022
Clinically Suspect Arthralgia Patients with a Low Educational Attainment Have an Increased Risk to Develop Inflammatory Arthritis
Sarah J.H. Khidir¹, Anna M.P. Boeren², Annelies Boonen³, Pascal de Jong⁴, Elise van Mulligen⁵ and Annette van der Helm-van Mil⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus MC, Rotterdam, Rotterdam, ³Maastricht University Medical Centre, Maastricht, Netherlands, ⁴ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁵Erasmus Medical Center, Leiden University Medical Center, Rotterdam, Netherlands, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Cross-sectional studies have shown that rheumatoid arthritis (RA) is more prevalent among people with a lower educational attainment. To date, no longitudinal data are…
Abstract Number: 0765 • ACR Convergence 2022
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Martina Frodlund¹, Katerina Chatzidionysiou², Anna Södergren³, Eva Klingberg⁴, Anders A Bengtsson⁵, Monika Hansson², Sophie Ohlsson⁶, Elisa Pin⁷, Lars Klareskog⁸ and Meliha Kapetanovic⁹, ¹Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ²Department of Medicine, Solna, Division of Rheumatology, Karolinska University Hospital at Karolinska Institutet, Stockholm, Sweden, ³Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden and Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁶Department of Clinical Sciences, Lund, Section for Nephrology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁷Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden
Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…
Abstract Number: 0885 • ACR Convergence 2022
Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study
brittany weber¹, Dana Weisenfeld¹, Thany Seyok¹, Elena Massarotti¹, Selena Huang¹, Derrick Todd¹, Jonathan Coblyn¹, michael weinblatt¹, Tianrun Cai¹, Kumar Dahal¹, leanne BArrett¹, Daniel Solomon¹, Jorge Plutzky¹, Marcy Bolster², marcelo Dicarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased cardiovascular (CV) risk. Coronary flow reserve (CFR) is a quantitative imaging biomarker of CV risk that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].